LOGIN  |  REGISTER
Assertio

Quest Diagnostics Completes Acquisition of Outreach Lab Services Business of Summa Health

November 28, 2022 | Last Trade: US$168.82 2.40 1.44
  • Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Northeastern Ohio

SECAUCUS, N.J. and AKRON, Ohio, Nov. 28, 2022 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a large integrated health system. Additional financial terms were not disclosed.

With the acquisition, Quest broadens access to diagnostic innovation and insights empowering better health for more communities in Northeastern Ohio. Physicians and patients will benefit from access to Quest's industry-leading and highly innovative test menu, network of patient access sites throughout the state, broad health plan coverage and lower out-of-pocket costs for many services. Quest's laboratories in Twinsburg, Ohio and Pittsburgh, Pennsylvania will provide testing for physicians and patients previously served by LabCare Plus.

About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com.

Viking Therapeutics

Stock Quote

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page